News and Press Releases

All | News | Press | Recruitment

Recent | Archive

Scientific publication: Characterization of a novel OX40 ligand and CD40 ligand-expressing oncolytic adenovirus used in PeptiCRAd cancer vaccine platform

ValoTx is pleased to share a new publication in Molecular Therapy Oncolytics (2021 in press) from IVTLab and Valo Therapeutics on PeptiCRAd technology and our proprietary oncolytic adenovirus platform. A link to the paper can be found here Abstract Oncolytic viruses (OVs) have been shown to induce anti-cancer immunity and enhance cancer immunotherapies, such as immune checkpoint inhibitor therapies. OV therapies can be further improved by arming OVs with immunostimulatory molecules including various cytokines or chemokines. Here, we have developed

10/2/21

News Article

Valo Therapeutics Granted USA Patent for PeptiCRAd Technology in Cancer Immunotherapy

Helsinki, 24th November, 2020 Valo Therapeutics, the developer of novel, adaptable immunotherapy platforms for cancer and infectious diseases, today announced that the US Patent Office has granted US Patent No 10,799,568 on 13 October 2020, covering its lead PeptiCRAd platform technology. The patent covers the use of adenoviral vectors having tumor-specific peptides attached to the viral capsid, for stimulating targeted anti-tumor immune responses in cancer patients. Patents for PeptiCRAd technology have been previously granted in Europe (No 3145537) and in

24/11/20

News Article

This Startup is Making a Cancer Vaccine out of Viruses

Valo Therapeutics is operating both in the UK and Finland to develop a cancer vaccine based on a virus designed to kill tumors.

29/3/20

News Article

Valo Therapeutics Receives Prize at the Third Annual Lyfebulb-Helsinn Cancer Innovation Summit & Awards

MONACO, PRINCIPALITY OF MONACO, AND NEW YORK, NY, USA, January 31, 2020: Lyfebulb, a patient empowerment platform that connects patients with industry to support user-driven innovation toward solutions in chronic disease, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, announce that Russell LaMontagne of Boston Immune Technologies and Therapeutics was chosen as the winner of the Lyfebulb-Helsinn Innovation Award, and Cesare Spadoni, PhD, of Oncoheroes Biosciences was chosen as the winner of the Squinto-LePera Award by

3/2/20

News Article

BioCentury Innovations Emerging Company Profile - "Valo: adding tumor antigens to oncolytic viruses"

BioCentury Innovations Emerging Company Profile "ValoTx: adding tumor antigens to oncolytic viruses" "With platforms that can rapidly display tumor-specific antigens on oncolytic viruses without genetic engineering, Valo is positioning itself as an attractive collaborator for immunooncology companies..." Read full article here: https://drive.google.com/file/d/1Ye_k2h4nUh9R5FxxpAlIqiH9ko5_xQtr/view?usp=sharing

26/9/19

News Article

Oncolytics: the dawn of a new era in cancer treatment

Published August 2, 2018 on pharmaphorum.com Oncolytic virus therapy is not a new discovery, but it may now be positioned as the next major breakthrough in cancer treatment following the success of checkpoint inhibitors in immunotherapy. An oncolytic virus is defined as a genetically engineered or naturally occurring virus that can selectively replicate and kill cancer cells without harming healthy tissues. In contrast to gene therapy, where a virus is used as a mere carrier for transgene delivery, oncolytic virus

6/8/18

News Article

Nature: Cancer-killing viruses show promise — and draw billion-dollar investment

Encouraging trial results spur interest from researchers and drug giants.

9/5/18

News Article

Valo Therapeutics is developing a virus-based immunotherapy to defeat cancer

There have been major developments in cancer treatment in recent years. However, treatment of advanced, metastasized tumours remains challenging, and still requires search for new solutions. Valo Therapeutics is currently developing an oncolytic virus-based immunotherapy that is scheduled to enter clinical trials in upcoming years.

14/9/17

News Article

Adenoviruses and the immune system join forces against cancer

IDIBELL researchers have developed an oncolytic virus capable of redirecting the patient's immune system against their tumor cells

17/2/17

News Article

Immuno-oncology News: Valo Therapeutics Developing Unique Viral-particle Cancer Vaccine

A new cancer vaccine that uses viral particles to trigger strong immune responses against cancer cells is being developed by Valo Therapeutics.

7/2/17

News Article

Drug Discovery and Development- "Immunotherapy: Training The Body to Fight Cancer"

Top researchers in the field of immuno-oncology show promising results using peptide / antibody vaccine combination treatments in terminally ill patients with metastatic tumours

6/2/17

News Article

Oncolytic Viruses "undervalued" technology with strong growth perspectives

Major acquisitions (>$1bn) have been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment.

25/1/17

News Article

BMS offers $850M for British Oncolytic Virus

BMS is offering PsiOxus Therapeutics a massive deal to get exclusive rights of an oncolytic virus that could outperform the promising CAR-T therapies.

24/11/16